Back to Newsroom

Alder BioPharmaceuticals Initiates Pivotal Clinical Trial of ALD403 for Preventative Treatment of Frequent Episodic Migraine

BOTHELL, Wash., Oct. 13, 2015 – Alder BioPharmaceuticals, Inc. (“Alder”) (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, Cushing’s disease, Congenital Adrenal Hyperplasia and autoimmune and inflammatory diseases, today announced the initiation of the first of two planned pivotal clinical trials of ALD403, its transformative monoclonal antibody targeting the calcitonin generelated peptide (CGRP), for the prevention of frequent episodic migraine. CGRP is a small protein involved in the transmission of and heightened sensitivity to pain experienced in migraine.

Click here to read more